top of page

Black Diamond Therapeutics' CEO on the company's 'MasterKey' approach to precision oncology

Mark Velleca describes Black Diamond's 'MasterKey' approach to precision oncology that's aimed at solving many mutations at once, and updates us on lead programs targeting EGFR and BRAF.



Comments


Join the BiotechTV mailing list

Thanks for subscribing!

bottom of page